Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.16 USD
Change Today -0.16 / -2.19%
Volume 25.5K
JNP On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

juniper pharmaceuticals inc (JNP) Snapshot

Open
$7.27
Previous Close
$7.32
Day High
$7.40
Day Low
$7.11
52 Week High
03/16/15 - $8.40
52 Week Low
01/12/15 - $5.09
Market Cap
77.1M
Average Volume 10 Days
17.9K
EPS TTM
$0.33
Shares Outstanding
10.8M
EX-Date
--
P/E TM
21.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for JUNIPER PHARMACEUTICALS INC (JNP)

Related News

No related news articles were found.

juniper pharmaceuticals inc (JNP) Related Businessweek News

No Related Businessweek News Found

juniper pharmaceuticals inc (JNP) Details

Juniper Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system and a segmented intra-vaginal ring technology. It develops and markets five bioadhesive gel products, including CRINONE, a progesterone gel for use in infertility, which is marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in approximately 60 countries worldwide. The company is also developing COL-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecological procedures. In addition, it provides pharmaceutical development, clinical trial supply manufacturing, and analytical services, as well as consultative services to its pharmaceutical industry customers. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

85 Employees
Last Reported Date: 03/18/15
Founded in 1986

juniper pharmaceuticals inc (JNP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Chief Operating Officer and Director
Total Annual Compensation: $86.0K
Compensation as of Fiscal Year 2013.

juniper pharmaceuticals inc (JNP) Key Developments

Juniper Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board

Juniper Pharmaceuticals, Inc. announced the creation of a Scientific Advisory Board comprised of internationally renowned physicians and scientists, whose mission will be to provide scientific and clinical advice on the identification and advancement of product candidates for Juniper's women's health portfolio. The SAB consists of the following distinguished members: Ginger D. Constantine, MD; William F. Crowley Jr., MD; Martyn Davies, BSc, Ph.D., FRPharmS, CChem, FRSC; Robert S. Langer, Sc.D.; and, Daniel A. Shames, MD, FACS. Ginger Constantine during her ten year tenure within the Wyeth Pharmaceuticals and Wyeth Research organizations, Dr. Constantine held various management positions of increasing responsibility in the therapeutic areas of rheumatology, metabolism and bone repair. She ultimately served as Vice President of Women's Health & Bone Repair Medical Research at Wyeth Research until its acquisition by Pfizer in 2010, guiding her staff to the completion of numerous Investigational New Drug Applications and more than ten New Drug Applications and European dossiers in the areas of contraception, osteoporosis, menopausal symptoms, endometriosis, and osteoarthritis. Crowley is the Daniel K. Podolsky Professor of Medicine at Harvard Medical School, where he also serves as the Chief of the Reproductive Endocrine Unit of the Department of Medicine at Massachusetts General Hospital (MGH). In addition, he is the Director of the Harvard-wide Reproductive Endocrine Sciences Center. He served as the Director of Clinical Research for the MGH for 17 years. During this time, Dr. Crowley founded and served as the first Chair of The Clinical Research Forum, a national consortium of the top 60 academic medical centers engaging in clinical and translation research. Davies is Professor of Biomedical Surface Chemistry at the University of Nottingham School of Pharmacy, and has over 30 years' experience in the pharmaceutical, biopharmaceutical and drug delivery fields. Dr. Davies co-founded Juniper Pharma Services in 1997 as a spin-out company from his academic laboratory, and served as its Founder-Chairman until its acquisition by Juniper Pharmaceuticals in September 2013, at which time he was appointed Advisor to the company's Board of Directors. Langer is the Massachusetts Institute of Technology Department of Chemical Engineering David H. Koch Institute Professor. Shames has extensive experience in pharmaceutical development and regulatory affairs. During his 12-year tenure at the FDA, he served as Deputy Director, Office of Drug Evaluation III/Center for Drug Evaluation and Research (CDER) from 2006 to 2008, and was a member of the senior management team of the Office of New Drugs and the Drug Safety Oversight Board.

Juniper Pharmaceuticals, Inc. Appoints Nikin Patel as Chief Operating Officer

On April 10, 2015, the Board of Directors of Juniper Pharmaceuticals Inc. (formerly known as Columbia Laboratories Inc.) has appointed Dr. Nikin Patel, age 42, as the company's new Chief Operating Officer, effective immediately. Dr. Patel is the founding Chief Executive Officer of Juniper Pharma Services (formerly known as Molecular Profiles Ltd.) and has held this position since October 1998. Dr. Patel has also been a director of the company since September 2013, when Juniper Pharma was acquired by the company. In addition to serving as a director of the company, Dr. Patel is currently a director of Regentec Ltd. (regenerative medicine), a position he has held since 2001.

Columbia Laboratories Adopts an Amendment to its Amended and Restated Bylaws

Columbia Laboratories Inc. adopted an amendment to its Amended and Restated Bylaws which will become effective April 10, 2015, to reflect the name change to Juniper Pharmaceuticals Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNP:US $7.16 USD -0.16

JNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.00 USD +0.31
View Industry Companies
 

Industry Analysis

JNP

Industry Average

Valuation JNP Industry Range
Price/Earnings 24.0x
Price/Sales 2.4x
Price/Book 1.9x
Price/Cash Flow 23.3x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUNIPER PHARMACEUTICALS INC, please visit www.juniperpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.